Targeted genome editing

Directed gene targeting in mammalian cells has been a big challenge for researchers engaged in cell engineering. In recent years, several gene targeting new technologies, such as ZFN, TALEN, and CRISPR / Cas9, result in a revolutionary change in the field of genome editing in mammalian cells. Using these new technologies, in particular the CRISPR / Cas9 technology, researchers can efficiently conduct genomic modification, such as gene knockout and knock-in, specific gene modifications, as well as site-directed transgene expression, etc.. 

CIB is a leading biotechnology company in China specialized in stem cell engineering, particularly in genetic modification of human pluripotent stem cells. As early as 2010, CIB researchers have collaborated with scientists from Guangzhou Institute of Biomedicine and Health (GIBH) and scientists from Sigma-Aldrich (a global leading company in genome editing) and successfully applied ZFN, TALEN, and CRISPR/Cas9 technologies to make genetic modifications on human iPSC. So far, we have created a series of genetically modified iPSC lines, including iPSC lines containing genetic defects that reassemble genetic mutations found in patients with Parkinson's disease and Alzheimer’s disease. Through years of efforts, we have mastered the ZFN, TALEN, and CRISPR / Cas9 technologies and particularly improved efficiency of gene knock-in using the CRISPR / Cas9 technology. Also, we have developed a highly efficient process for iPSC single cell cloning and characterization.

 Using sophisticated genetic modification technology, combined with our extensive experience in iPSC engineering, we are able to quickly and efficiently conduct genome modifications on CIB iPSC cell lines or iPSC lines provided by customers.


For availability and purchase information of all CIB neural cell products please contact:


Copyright 2008-2013 of Shenzhen city and three biological technology Co., Ltd. all rights reserved. All Rights Reserved